Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Amgen, Nektar Sign Drug Polymer Pact

by Lisa M. Jarvis
November 8, 2010 | A version of this story appeared in Volume 88, Issue 45

Amgen will pay Nektar Therapeutics, a San Carlos, Calif.-based biotech firm with polymer-conjugate chemistry technology, $50 million to make PEGylation materials on a nonexclusive basis. Under the 10-year pact, Nektar will manufacture the polymers in its Huntsville, Ala., facility. Nektar could be eligible for additional payments if Amgen needs more than the agreed-upon quantities. Amgen uses the polymers in the manufacture of Neulasta, a treatment used to prevent infection in patients undergoing chemotherapy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.